myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners NEW YORK and SALT LAKE CITY, March 09, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the

Data highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney disease patients beyond commonly used markers UACR and historical eGFR change over time NEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42 nd Annual Health Care Conference. Renalytix’s management is scheduled to participate

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

American Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study (CANVAS) multinational clinical trial cohort patients NEW YORK and SALT LAKE CITY, Jan.

Seventh KidneyIntelX implementation partnership for Renalytix focused on underserved populations with high disease burden GULF COAST, Miss. and SALT LAKE CITY, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singing River Health System and Renalytix (NASDAQ: RNLX) (LSE: RENX)  today announced a partnership to

NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix’s global

NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40 th Annual J.P. Morgan Virtual Healthcare Conference.

National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes ARLINGTON, Va. and SALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The American Diabetes